Table 3 Relationship of clinical characteristics with biomarkers and neuropsychiatric performances in patients with temporal lobe epilepsy
| Â | Seizure frequency | Duration of epilepsy | |
|---|---|---|---|
|  | Group 1 (n = 22) | Group 2 (n = 12) | σ coefficient |
Duration of epilepsy (years) | 16.7 ± 8.5 | 20.3 ± 13.6 | - |
Number of antiepileptic drugs used Biomarkers | 1.6 ± 0.6 | 2.52 ± 0.7 | -0.029 |
   Heat shock protein 70 (µg/ml) | 123.4 ± 34.7 | 324.7 ± 97.4** | 0.413†|
   Non-specific enolase (ng/ml) | 8.4 ± 1.2 | 11.3 ± 1.13** | 0.062 |
   S100 ß protein (pg/ml) | 79.04 ± 12.5 | 148.95 ± 43.6** | 0.132 |
   Plasma nuclear DNA (ng/ml) | 29.22 ± 2.2 | 30.33 ± 2.2 | 0.18 |
   Plasma mitochondrial DNA (ng/ml) | 21.04 ± 1.0 | 21.13 ± 1.1 | 0.044 |
Verbal Memory CVLT-MS (9) | Â | Â | Â |
   30 sec free recall | 7.86 ± 1.5 | 7.27 ± 2.8 | 0.041 |
   10-min free recall | 7.23 ± 1.9 | 7.09 ± 2.9 | 0.045 |
   10-min recognition | 7.50 ± 2.0 | 7.64 ± 1.6 | 0.153 |
Modified Rey-Osterrieth recall (17) | 16.77 ± 0.8 | 16.82 ± 0.6 | 0.3020 |
Cube copy (2) | 0.91 ± 0.9 | 1.18 ± 0.9 | -0.068 |
Pentagon copy (1) | 0.82 ± 0.4 | 0.82 ± 0.4 | -0.469†|
Semantic fluency animal (1 minute) | 14.09 ± 4.5 | 17.73 ± 6.6 | -0.342 |
Boston naming test (16) | 14.36 ± 2.3 | 14.18 ± 2.4 | -0.175 |
Comprehension (4) | 3.45 ± 0.9 | 3.45 ± 1.0 | -0.631†|
Abstract thinking (3) | 1.95 ± 1.2 | 2.27 ± 1.2 | -0.347 |
Problem solving (3) | 2.00 ± 1.0 | 2.00 ± 1.18 | 0.107 |
Stroop interference correct (1 minute) | 39.82 ± 16.5 | 42.64 ± 12.4 | -0.374 |
Design fluency | 7.68 ± 5.7 | 9.00 ± 5.8 | -0.350 |
Trail Making test time (< 120 seconds) | 51.68 ± 38.8 | 45.18 ± 32.1 | 0.548†|
Digit forward | 7.27 ± 1.5 | 7.73 ± 1.1 | -0.346 |